

Effect of glucose deprivation on the expression of genes encoding glucocorticoid receptor and some related factors in ERN1-knockdown U87 glioma cells

Olena O. RIABOVOL¹, Dariia O. TSYMBAL¹, Dmytro O. MINCHENKO^{1,2}, Kateryna M. LEBID-BILETSKA¹, Myroslava Y. SLIUSAR¹, Olha V. RUDNYTSKA¹, Oleksandr H. MINCHENKO¹

¹Department of Molecular Biology, Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine; ²Department of Pediatrics, National Bohomolets Medical University, Kyiv, Ukraine

E-mail: ominchenko@yahoo.com

Objective. The aim of the present study was to examine the effect of glucose deprivation on the expression of genes encoded glucocorticoid receptor (NR3C1) and some related proteins (NR3C2, AHR, NRIP1, NNT, ARHGAP35, SGK1, and SGK3) in U87 glioma cells in response to inhibition of endoplasmic reticulum stress signaling mediated by ERN1/IRE1 (endoplasmic reticulum to nucleus signaling 1/inositol requiring enzyme 1) for evaluation of their possible significance in the control of glioma growth through endoplasmic reticulum stress signaling mediated by IRE1 and glucose deprivation.

Methods. The expression of NR3C1, NR3C2, AHR, NRIP1, NNT, ARHGAP35, SGK1, and SGK3 genes in U87 glioma cells transfected by empty vector pcDNA3.1 (control cells) and cells without ERN1 signaling enzyme function (transfected by dnERN1) under glucose deprivation was studied by real time quantitative polymerase chain reaction.

Results. It was shown that the expression level of NR3C2, AHR, SGK1, SGK3, and NNT genes was up-regulated in control U87 glioma cells under glucose deprivation condition in comparison with the control cells growing with glucose. At the same time, the expression of NRIP1 gene is down-regulated in these glioma cells under glucose deprivation, but NR3C1 and ARHGAP35 genes was resistant to this experimental condition. We also showed that inhibition of ERN1 signaling enzyme function significantly modified the response of most studied gene expressions to glucose deprivation condition. Thus, effect of glucose deprivation on the expression level of NR3C2, AHR, and SGK1 genes was significantly stronger in ERN1 knockdown U87 glioma cells since the expression of NNT gene was resistant to glucose deprivation condition. Moreover, the inhibition of ERN1 enzymatic activities in U87 glioma cells led to up-regulation of ARHGAP35 gene expression and significant down-regulation of the expression of SGK3 gene in response to glucose deprivation condition.

Conclusions. Results of this study demonstrated that glucose deprivation did not change the expression level of NR3C1 gene but it significantly affected the expression of NR3C2, AHR, NRIP1, SGK1, SGK3, and NNT genes in vector-transfected U87 glioma cells in gene specific manner and possibly contributed to the control of glioma growth since the expression of most studied genes in glucose deprivation condition was significantly dependent on the functional activity of IRE1 signaling enzyme.

Key words: glucose deprivation, mRNA expression, NR3C1, NR3C2, AHR, NRIP1, SGK1, SGK3, ARHGAP35, NNT, ERN1 inhibition, U87 glioma cells

Malignant gliomas are highly aggressive tumors with very poor prognosis and to date, there is no efficient treatment available (Nayak and Reardon 2017; Alimohammadi et al. 2019). Therefore, the moderate efficacy of conventional clinical approaches underlines the need for new therapeutic strategies. Cell proliferation is strongly dependent on the glycolysis and glucose level, because there is the molecular connection between the cell cycle progression and the provision of nutrients essential for this purpose. Glucose as well as glutamine are important substrates for glycolysis and glutaminolysis, which are important to glioma development and a more aggressive behavior through regulation of the cell cycle at distinct stages (Colombo et al. 2011; Yalcin et al. 2014; Zhao et al. 2017). It has been shown that down-regulation of glucose transporter 1 by microRNA miR-451 inhibits the glucose metabolism and proliferation as well as invasion of glioma cells (Guo et al. 2016). Glucose shortage associated with malignant progression triggers apoptosis through the endoplasmic reticulum unfolded protein response, particularly by inducing the unfolded protein response transcription factors ATF4 and CHOP as well as through the cystine/glutamate transporter SLC7A11 (solute carrier family 7 member 11) as a key regulator of EPH Receptor A2 (EPHA2) (Huber et al. 2013; Iurlaro et al. 2017; Teramoto and Katoh 2019). Furthermore, a better knowledge of tumor responses to glucose deprivation conditions is required to elaborate therapeutic strategies of cell sensibilization, based on the blockade of survival mechanisms (Huber et al. 2013; Tsybal et al. 2016; Iurlaro et al. 2017; Teramoto and Katoh 2019).

The growing tumor requires the endoplasmic reticulum stress for own neovascularization and growth and apoptosis inhibition because it has an important position as a signal integrator in both the normal and malignant cells (Drogat et al. 2007; Auf et al. 2010). The endoplasmic reticulum stress signaling pathways have connections with other plasma membrane receptor signaling networks and numerous metabolic pathways (Bravo et al. 2013; Minchenko et al. 2013; Chevet et al. 2015). Malignant tumors use endoplasmic reticulum stress response and its signaling pathways to adapt and enhance tumor cells proliferation under stressful environmental conditions (Manie et al. 2014; Dejeans et al. 2015). It is well known that activation of IRE1/ERN1 (inositol requiring enzyme 1/endoplasmic reticulum to nucleus signaling 1) branch of the endoplasmic reticulum stress response is tightly linked to apoptosis and cell death and suppression of its function

has been demonstrated to result in a significant anti-proliferative effect in glioma growth (Moenner et al. 2007; Auf et al. 2010, 2013; Minchenko et al. 2014, 2015a, 2015b).

Receptor for glucocorticoids (nuclear receptor subfamily 3, group C, member 1; NR3C1) has a dual mode of action: 1) as a transcription factor that binds to glucocorticoid response elements and 2) as a modulator of other transcription factors. It plays an important role in the regulation of numerous metabolic and proliferative processes, including tumorigenesis and metabolic diseases, such as obesity and diabetes, preferentially as a transcription factor that binds to glucocorticoid response element in the target genes, both for the nuclear and mitochondrial DNA (de Guia and Herzig 2015; Pufall 2015; Thomas et al. 2015; Liang et al. 2017). It affects inflammatory responses, cellular proliferation, and differentiation in target tissues. Unlike other steroid hormone receptors, the glucocorticoid receptor is not considered to be an oncogene. There are data indicating that miR-124 might contribute to the glucocorticoid resistance by promoting the proliferation and inhibiting the apoptosis (Vonlanthen et al. 2014; Kim et al. 2015; Huang et al. 2016; Liang et al. 2017). Furthermore, it has also been shown that NR3C1 is a key component of the regulatory pathway for signal transmission in mitochondria and that glucocorticoids can stimulate directly the mitochondrial transcription by the mitochondrially localized glucocorticoid receptors (Minchenko and Germanyuk 1984; Minchenko 1988; Minchenko and Tronjko 1988; Psarra and Sekeris 2011; Qi and Ding, 2017). Moreover, glucocorticoid receptors can also be a signal by binding to other transcription factors and modulate the transcriptional regulation of target genes (Khan et al. 2011; Li et al. 2012; Dasgupta et al. 2015).

It has been shown that human mineralocorticoid receptor (NR3C2) has functional kinship with the glucocorticoid receptor and shows high affinity for glucocorticoids as well as ability to stimulate a glucocorticoid-responsive promoter (Arriza et al. 1987). The mineralocorticoid receptors together with glucocorticoid ones provide unexpected functional diversity, in which hormone-binding properties, target gene interactions, and patterns of tissue-specific expression may be used in a combinatorial fashion to achieve complex physiologic control (Arriza et al. 1987; Le Billan et al. 2018). Thus, both receptors dynamically and cyclically interact at the same promoter of period circadian protein 1 (PER1), a target gene in a specific and distinct transcriptional signature (Le Billan et al. 2018). Furthermore, during

this process, both receptors regulate PER1 gene by binding as homo- or heterodimers to the same promoter region. There are also data demonstrating that epidermal growth factor (EGF) administration increases the mineralocorticoid receptor transcriptional activity through EGFR/ERK pathway and that targeting of NR3C2 by microRNA-766 promotes cancer progression in hepatocellular carcinoma (Mitsuishi *et al.* 2018; Yang *et al.* 2019).

There are data indicating that ARHGAP35 (Rho GTPase Activating Protein 35), also known as glucocorticoid receptor DNA binding factor 1 (GRF-1), acts as a tumor suppressor gene, associates with the promoter region of the glucocorticoid receptor gene and represses transcription of the glucocorticoid receptor by binding to the cis-acting regulatory sequence (Organ *et al.* 2014; Zhao *et al.* 2014; Choi *et al.* 2018; Onodera *et al.* 2018). Moreover, there is a regulatory cross-talk between the glucocorticoid receptor and aryl hydrocarbon receptor (AHR) in HepG2 cells because cellular signaling by these receptors shares several functional and regulatory features (Dvorak *et al.* 2018). There are data showing that the glucocorticoids increase AHR levels in hepatoma cells via a glucocorticoid receptor-dependent transcriptional mechanism (Dvorak *et al.* 2018). Furthermore, it has been shown that AHR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer and that the chemical inhibition of AHR activity sensitizes human breast cancer models to Erlotinib, a selective EGFR tyrosine kinase inhibitor, suggesting a promising combinatorial anticancer effect of AHR and EGFR pathway inhibition (Kubli *et al.* 2019).

Nuclear receptor interacting protein 1 (NRIP1) is a nuclear protein that is expressed in a circadian manner and specifically interacts with the hormone-dependent activation domain AF2 of nuclear receptors NR3C1, NR3C2, and ESR1 (estrogen receptor) and modulates their transcriptional activity. It is a positive regulator of the circadian clock genes and its expression is altered in breast cancers (Jalaguier *et al.* 2017; Muller *et al.* 2019). Moreover, NRIP1 plays a critical role in promoting the progression and development of breast cancer because suppressing of NRIP1 inhibits growth of breast cancer cells both *in vitro* and *in vivo* (Aziz *et al.* 2015). There are data demonstrating that mutations in *NNT* (nicotinamide nucleotide transhydrogenase) gene cause familial glucocorticoid deficiency because it is a key regulator of adrenal redox homeostasis and steroidogenesis (Meimaridou *et al.* 2012, 2018; Weinberg-Shukron *et al.* 2015). The NNT is an integral protein of the

inner mitochondrial membrane and functions as a proton pump across the membrane. It has also been shown that NNT plays a crucial role in the tumor progression and that knockdown of NNT significantly reduced NADPH, increased the level of reactive oxygen species and cell apoptosis under oxidative stress conditions, such as glucose deprivation (Li *et al.* 2018a).

Glucocorticoids are responsible for the regulation of SGK1 and SGK3 (serum/glucocorticoid regulated kinases 1 and 3), which also are induced by a very large spectrum of stimuli distinct from glucocorticoids and serum (Liu *et al.* 2015; Xiaobo *et al.* 2016; Cao *et al.* 2019; Fan *et al.* 2019). It has been shown that Src (SRC proto-oncogene, non-receptor tyrosine kinase) positively regulates SGK1 expression in triple negative breast cancer cells, which exhibit a prominent signaling network governed by Src family kinases (Ma *et al.* 2019).

The aim of the present study was to examine the effect of glucose deprivation on the expression of genes encoded glucocorticoid receptor (NR3C1) and some related proteins (NR3C2, AHR, NRIP1, NNT, ARHGAP35, SGK1, and SGK3) in U87 glioma cells in response to inhibition of ERN1 for evaluation of their possible significance in the control of glioma growth through endoplasmic reticulum stress signaling mediated by IRE1 and glucose deprivation.

Materials and methods

Cell lines and culture conditions. The glioma cell line U87 was obtained from ATCC (USA) and grown in high glucose (4.5 g/l) Dulbecco's modified Eagle's minimum essential medium (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with glutamine (2 mM), 10% fetal bovine serum (Equitech-Bio, Inc., USA), penicillin (100 units/ml; Gibco) and streptomycin (0.1 mg/ml; Gibco) at 37°C in incubator with 5% CO₂. In this work, we used two sublines of this glioma cells. One subline was obtained by selection of stable transfected clones with overexpression of vector pcDNA3.1, which was used for creation of dnERN1. This untreated subline of glioma cells (control glioma cells) was used as control 1 in the study of the effect of glucose deprivation on the expression level of genes encoding glucocorticoid receptor (NR3C1) and some related proteins (NR3C2, AHR, NRIP1, NNT, ARHGAP35, SGK1, and SGK3). Second subline was obtained by selection of stable transfected clone with overexpression of ERN1 dominant/negative construct (dnERN1) and has suppressed both protein kinase and endoribonuclease activities of this signaling enzyme

(Auf et al. 2010). The expression level of studied genes in dnERN1 cells exposure under glucose deprivation condition was compared with these cells growing with glucose (Control 2). The efficiency of ERN1 suppression in this glioma cell subline was estimated previously (Auf et al. 2010, 2013) by determining the expression level of the XBP1 alternative splice variant, a key transcription factor in the ERN1 signaling, and the level of the phosphorylated isoform ERN1 using cells treated by tunicamycin (0.01 mg/ml during 2 h). Both used in this study sublines of glioma cells are grown in the presence of geneticin (G418) while these cells carrying empty vector pcDNA3.1 or dn-ERN1 construct.

Glucose deprivation condition was created by changing the complete DMEM medium into culture plates on DMEM medium without glucose (Gibco) and plates were exposed to this condition for 16 hrs.

RNA isolation. Total RNA was extracted from glioma cells using the Trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA pellets were washed with 75% ethanol and dissolved in nuclease-free water. For additional purification RNA samples were re-precipitated with 95% ethanol and re-dissolved again in nuclease-free water. RNA concentration and spectral characteristics were measured using NanoDrop Spectrophotometer ND1000 (PEQLAB, Biotechnologie GmbH).

Reverse transcription and quantitative PCR analysis. The effect of glucose deprivation on the expression levels of glucocorticoid receptor (NR3C1) and related proteins (NR3C2, ARHGAP35, AHR, NRIP1, NNT, SGK1, and SGK3 mRNAs as well as ACTB mRNA were measured in control U87 glioma cells and cells with a deficiency of ERN1 by quantitative polymerase chain reaction using SYBRGreen Mix (ABgene, Thermo Fisher Scientific, Epsom, Surrey, UK) and qPCR „RotorGene RG-3000” (Corbett Research, Germany) and “QuantStudio 5 Real-Time PCR System” (Applied Biosystems, USA). QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany) and Thermo Scientific Verso cDNA Synthesis Kit was used for reverse transcription as described previously (Minchenko et al. 2015, 2019). Polymerase chain reaction was performed in triplicate. The expression of beta-actin mRNA was used as control of analyzed RNA quantity. The pair of primers specific for each studied gene was received from Sigma-Aldrich (St. Louis, MO, U.S.A.) and used for quantitative polymerase chain reaction (Table 1).

Quantitative PCR analysis was performed using a special computer program “Differential expression calculator” and statistical analysis – as described previously (Bochkov et al. 2006). The values of NR3C1, NR3C2, ARHGAP35, AHR, NRIP1, NNT, SGK1, and SGK3 gene expressions were normalized

Table 1
Characteristics of the primers used for quantitative real-time polymerase chain reaction

Gene symbol	Gene name	Primer's sequence	Nucleotide numbers in sequence	GenBank accession number
NR3C1	nuclear receptor subfamily 3 group C member 1 (glucocorticoid receptor)	F: 5'-ttccctcctgctcctctg R: 5'-tcacatctcccctcctga	382–401 571–552	NM_000176
NR3C2	nuclear receptor subfamily 3 group C member 2 (mineralocorticoid receptor 1)	F: 5'-tcctgcttgacagactcaga R: 5'-gaggaaccagtgcgtgtgtg	2222–2241 2433–2414	NM_000901
ARHGAP35	Rho GTPase activating protein 35 (glucocorticoid receptor DNA binding factor 1)	F: 5'-ggcaacctgggagagtaact R: 5'-agtctttctctgccaggtcc	3717–3736 3934–3915	NM_004491
AHR	aryl hydrocarbon receptor (class E basic helix-loop-helix protein 76)	F: 5'-cttccaagcgcatagagac R: 5'-agttatcctggcctccgttt	717–736 914–895	NM_001621
NRIP1	nuclear receptor interacting protein 1	F: 5'-ctccggatgacatcagagct R: 5'-cgcaaggaggaggagaagaa	180–199 390–371	NM_003489
NNT	nicotinamide nucleotide transhydrogenase (NAD(P) transhydrogenase, mitochondrial)	F: 5'-gtctcctgaaatctgccct R: 5'-cagcacagtataacgacgg	2549–2568 2769–2750	NM_012343
SGK1	serum/glucocorticoid regulated kinase 1	F: 5'-gcagaaggacaggacaaagc R: 5'-tcggtaaactcgggtcaaa	1085–1104 1261–1242	NM_005627
SGK3	serum/glucocorticoid regulated kinase family member 3	F: 5'-attcccagctccgatgaaca R: 5'-tcgtttagtctcgtctct	312–331 547–528	NM_013257
ACTB	beta-actin	F: 5'-ggacttcgagcaagatgg R: 5'-agcactgtgttggcgtacag	747–766 980–961	NM_001101

to the expression of beta-actin mRNA and represent as percent of control (100%). All values are expressed as mean \pm SEM from triplicate measurements performed in 4 independent experiments. The amplified DNA fragments were also analyzed on a 2% agarose gel and that visualized by SYBR⁺ Safe DNA Gel Stain (Life Technologies, Carlsbad, CA, USA).

Results

To investigate a possible role of glucose deprivation and endoplasmic reticulum stress signaling mediated by ERN1 bifunctional enzyme in the expression level of mRNA for glucocorticoid receptor and related proteins, we studied the effect of glucose deprivation on expression of these genes in U87 glioma cells with and without ERN1 functional activity. As shown in Figure 1, the expression of NR3C1 mRNA in control, transfected by empty vector pcDNA3.1, U87 glioma cells is resistant to glucose deprivation in comparison with the cells growing in complete DMEM medium. Furthermore, inhibition of ERN1 signaling enzyme function does not significantly change the sensitivity of glucocorticoid receptor gene expression to this

experimental condition (Figure 1). We next investigated the effect of glucose deprivation on the expression of gene encoding mineralocorticoid receptor (NR3C2) in relation to inhibition of ERN1 function. As shown in Figure 2, the expression of NR3C2 mRNA is strongly up-regulated under glucose deprivation (+75%) in transfected by empty vector pcDNA3.1 U87 glioma cells in comparison with these cells growing in complete DMEM medium. More significant changes were observed in glioma cells with ERN1 knockdown (+109%) as compared to cells growing in glucose-containing medium (Figure 2).

We also studied the effect of glucose deprivation on the expression glucocorticoid receptor DNA binding factor 1 (GRLF1), also known as Rho GTPase Activating Protein 35 (ARHGAP35), in relation to functional activity of ERN1 signaling enzyme. As also shown in Figure 3, the expression level of ARHGAP35 mRNA is resistant to glucose deprivation condition in glioma cells transfected by empty vector. At the same time, inhibition of ERN1 signaling enzyme function leads to up-regulation of ARHGAP35 (+24%) gene expression in cells exposure under glucose deprivation condition.




Figure 1. Effect of glucose deprivation on the expression level of glucocorticoid receptor (nuclear receptor subfamily 3, group C, member 1; NR3C1) mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnERN1 measured by qPCR. Values of NR3C1 mRNA expressions were normalized to beta-actin mRNA level and represented as percent for control 1 (100%); n=4.




Figure 2. Effect of glucose deprivation on the expression level of mineralocorticoid receptor (nuclear receptor subfamily 3, group C, member 2; NR3C2) mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnERN1 measured by qPCR. Values of NR3C2 mRNA expressions were normalized to beta-actin mRNA level and represented as percent for control 1 (100%); n=4.

Investigation of AHR (aryl hydrocarbon receptor) gene encoding poly-functional protein, which can interact with glucocorticoid receptor in many essential physiological processes, showed its sensitivity to glucose deprivation (Figure 4). Thus, the expression level of *AHR* gene is significantly up-regulated (+47%) by glucose deprivation in glioma cells transfected by empty vector in comparison with cells growing with complete DMEM medium. Moreover, inhibition of ERN1 signaling enzyme function by dnER1 strongly enhances effect of glucose deprivation on this gene expression (+124%; Figure 4). At the same time, glucose deprivation leads to down-regulation of the expression level of *NR1P1* gene in glioma cells with functional ERN1 (–29%) in comparison with cells growing in complete DMEM medium (Figure 5). It was also shown that inhibition of ERN1 signaling enzyme function does not significantly change the effect of glucose deprivation on the expression level of *NR1P1* gene in glioma cells (–26%). We also studied the effect of glucose deprivation on the expression of *NNT* gene in glioma cells in relation to inhibition of ERN1 signaling enzyme function. As shown in

Figure 6, exposure glioma cells transfected by empty vector under glucose deprivation condition leads to small but statistically significant up-regulation of the expression *NNT* gene (+17%) in comparison with control cells growing in complete medium. We also found that inhibition of ERN1 signaling eliminates sensitivity of *NNT* gene expression to glucose deprivation condition (Figure 6).

We next investigated the effect of glucose deprivation on the expression of gene encoding serum/glucocorticoid regulated kinases 1 and 3 (SGK1 and SGK3) in glioma cells in relation to inhibition of ERN1 signaling enzyme function. It was shown that in control glioma cells (transfected by empty vector) the expression level of *SGK1* gene is up-regulated (+32%) under glucose deprivation in comparison with cells growing in complete medium and similar but slightly lesser effect was observed on *SGK3* gene expression (+24%) (Figure 7 and Figure 8). At the same time, inhibition of ERN1 signaling enzyme function significantly enhances effect of glucose deprivation on *SGK1* gene expression (+90%; Figure 7), on the other hand, the expression of *SGK3* gene in glioma




Figure 3. Effect of hypoxia on the expression level of Rho GT-Pase Activating Protein 35 (ARHGAP35), also known as glucocorticoid receptor DNA binding factor 1 (GRLF1), mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnER1 measured by qPCR. Values of ARHGAP35 mRNA expressions were normalized to beta-actin mRNA level and represent as percent for control 1 (100%); n=4.




Figure 4. Effect of hypoxia on the expression level of aryl hydrocarbon receptor (AHR), also known as class E basic helix-loop-helix protein 76, mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnER1 measured by qPCR. Values of AHR mRNA expressions were normalized to beta-actin mRNA level and represented as percent for control 1 (100%); n=4.




Figure 5. Effect of hypoxia on the expression level of nuclear receptor interacting protein 1 (NRIP1) mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnERN1 measured by qPCR. Values of NRIP1 mRNA expressions were normalized to beta-actin mRNA level and represented as percent for control 1 (100%); n=4.




Figure 6. Effect of hypoxia on the expression level of nicotinamide nucleotide transhydrogenase (NNT), also known as NAD(P) transhydrogenase, mitochondrial, mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnERN1 measured by qPCR. Values of NNT mRNA expressions were normalized to beta-actin mRNA level and represented as percent for control 1 (100 %); n=4.

cells with inhibited ERN1 signaling enzyme function is down-regulated (–39%) in comparison to cells growing with glucose (Figure 8).

Thus, glucose deprivation affects the expression of most studied genes and inhibition of endoplasmic reticulum stress signaling mediated by ERN1 signaling enzyme modifies the effect of glucose deprivation on the expression of almost all glucocorticoid receptor related factors in gene-specific manner: enhances effect of glucose deprivation on *NR3C2*, *AHR*, and *SGK1* genes in U87 glioma cells, introduces sensitivity of *ARHGAP35* gene, eliminates sensitivity of *NNT* gene, and suppresses the expression of *SGK3* gene.

Discussion

In this work, we studied the effect of glucose deprivation on the expression of genes encoded glucocorticoid receptor and a subset of related factors, which have relation to its functional activity, in relation to inhibition of ERN1, the major signaling pathway of the unfolded protein response, in U87 glioma cells. It is important to evaluate the significance of these

genes in the control of glioma growth through endoplasmic reticulum stress signaling mediated by ERN1 and glucose level because stress signaling pathways is involved in numerous metabolic pathways and inhibition of the activity of ERN1 signaling enzyme in glioma cells had anti-tumor effects (Auf et al. 2010, 2013; Bravo et al. 2013; Manie et al. 2014; Minchenko et al. 2013, 2014, 2015a,b). In addition, glucose is an important indicator of the cancer cells chemoresistance (Awale et al. 2006a,b).

Results of this study demonstrate that growing of glioma cells in glucose-deprived medium affects the expression of most genes studied in a gene specific manner. Thus, glucose deprivation leads to the up-regulation of the expression of *NR3C2*, *AHR*, *NNT*, *SGK1*, and *SGK3* genes and down-regulation of *NRIP1* gene (Figure 9). At the same time, the expression of genes encoding glucocorticoid receptor and glucocorticoid receptor DNA binding factor 1 (*ARHGAP35*) is resistant to glucose deprivation. Furthermore, inhibition of ERN1 signaling enzyme function significantly modifies the effect of glucose deprivation on the expression level of all genes studied, except the *NR3C1* and *NRIP1* genes (Figure 9), indi-




Figure 7. Effect of hypoxia on the expression level of serum/glucocorticoid regulated kinase 1 (SGK1) mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnERN1 measured by qPCR. Values of SGK1 mRNA expressions were normalized to beta-actin mRNA level and represented as percent for control 1 (100%); n=4.




Figure 8. Effect of hypoxia on the expression level of serum/glucocorticoid regulated kinase family, member 3 (SGK3) mRNA in control U87 glioma cells (Vector) and cells with a blockade of the ERN1 by dnERN1 measured by qPCR. Values of SGK3 mRNA expressions were normalized to beta-actin mRNA level and represented as percent for control 1 (100%); n=4.




Figure 9. Schematic demonstration of NR3C1, NR3C2, AHR, NRIP1, NNT, ARHGAP35, SGK1, and SGK3 genes expression profile in control and ERN1 knockdown glioma cells under glucose deprivation; NS – no significant changes.

cating their participation in ERN1 mediated network of unfolded protein response and possible contribution in the control of glioma cell proliferation. All proteins encoding by these genes are multifunctional and it is possible that different sensitivity of these gene expressions to glucose deprivation is associated with their specific functions in glioma cells. Thus, receptor for glucocorticoids (NR3C1) functions, as a transcription factor and also a modulator of other transcription factors, plays an important role in the regulation of numerous metabolic and proliferative processes, including tumorigenesis and metabolic diseases (de Guia and Herzig 2015; Pufall 2015; Huang et al. 2016; Liang et al. 2017). It is possible that resistance of NR3C1 to glucose deprivation in glioma cells is associated with an important multifunctional role of this receptor.

We showed that the mineralocorticoid receptor gene expression is very sensitive to glucose deprivation and this sensitivity is enhanced by ERN1 knockdown. This receptor has functional kinship with the glucocorticoid receptor and can stimulate the glucocorticoid-responsive promoter. Thus, interaction of both receptors in a combinatorial fashion allows achieving complex physiologic control (Arriza et al. 1987; Le Billan et al. 2018). At the same time, the mineralocorticoid receptor participates in tumor growth because targeting of NR3C2 by microRNA-766 promotes cancer progression in hepatocellular carcinoma (Mitsuishi et al. 2018; Yang et al. 2019). This up-regulation of NR3C2 gene expression in glioma cells under glucose deprivation condition correlates well with anti-proliferative function of mineralocorticoid receptor as well as with anti-proliferative effect of ERN1 inhibition (Auf et al. 2010, 2013; Minchenko et al. 2015a,b,c; Yang et al. 2019). We also found that the expression of glucocorticoid receptor DNA binding factor 1 (ARHGAP35) is increased in ERN1 knockdown glioma cells. This data correlate well with its functional role as a tumor suppressor (Choi et al. 2018; Onodera et al. 2018).

It is possible that increased expression of *AHR* gene in glioma cells under glucose deprivation and more significant up-regulation of this gene expression after ERN1 knockdown contributes to the suppression of proliferation and glioma growth from cells with inhibited ERN1 function (Auf et al. 2010, 2013; Minchenko et al. 2015a,c). These results conform the data that *AHR* has mainly anti-proliferative functions through interaction with different proteins and EGFR pathway (Dvorak et al. 2018; Kubli et al. 2019).

It is interesting to note that glucose deprivation leads to a down-regulation of *NR1P1* gene indepen-

dently from ERN1 inhibition. It is a nuclear protein that specifically interacts with the hormone-dependent activation domain of nuclear receptors NR3C1, NR3C2, and ESR1 and modulates their transcriptional activity. The NR1P1 protein is a positive regulator of the circadian clock genes and plays a critical role in promoting the progression and development of breast cancer because its expression is altered in breast cancers and suppressing of NR1P1 inhibits growth of breast cancer cells (Aziz et al. 2015; Jalaguier et al. 2017; Muller et al. 2019). Our data about down-regulation of *NR1P1* gene expression under glucose deprivation conform well the pro-proliferative role of NR1P1 protein. We also showed that the expression of NNT, which is an integral protein of the inner mitochondrial membrane, is up-regulated in glioma cells under glucose deprivation condition and that ERN1 knockdown eliminates this effect. It is possible that increased expression of *NNT* under glucose deprivation is connected with pro-oncogenic role of this protein and its important function in mitochondria (Li et al. 2018a).

We also observed up-regulation of serum/glucocorticoid regulated kinases 1 and 3 (SGK1 and SGK3), which also are induced by a very large spectrum of stimuli distinct from the glucocorticoids and serum (Liu et al. 2015; Xiaobo et al. 2016; Cao et al. 2019; Fan et al. 2019). Both kinases have pro-oncogenic properties: SGK1 expression is positively regulated in the triple negative breast cancer cells by SRC proto-oncogene, non-receptor tyrosine kinase and down-regulation of SGK3 through overexpression of miR-376a inhibits RCC cell proliferation, migration, and invasion (Fan et al. 2019; Ma et al. 2019). Thus, up-regulation of the expression of these multifunctional kinases (SGK1 and SGK3) in glioma cells under glucose deprivation conforms well to pro-proliferative role of these proteins. At the same time, inhibition of ERN1 signaling enzyme function has strong but different effect on their expression indicating ERN1 dependent character of these gene expressions and variable role in ERN1 signaling (Chen et al. 2018; Li et al. 2018b; Cao et al. 2019; Fan et al. 2019; Ma et al. 2019).

We showed that glucose deprivation condition up-regulates the expression of most genes studied and that inhibition of endoplasmic reticulum stress signaling mediated by ERN1 signaling enzyme modifies the effect of glucose deprivation on the expression of almost all the glucocorticoid receptor related factors in gene-specific manner, i.e. enhances the effect of glucose deprivation on NR3C2, *AHR*, and *SGK1* genes in U87 glioma cells, introduces

sensitivity of *ARHGAP35* gene, eliminates sensitivity of *NNT* gene, and suppresses the expression of *SGK3* gene.

This study provides unique insights into the molecular mechanisms regulating the expression of genes encoded glucocorticoid receptor and some related proteins in glucose deprivation condition and their correlation with reduced cell proliferation in cells

harboring dnERN1, attesting to the fact that endoplasmic reticulum stress is a necessary component of the malignant tumor growth and cell survival. Moreover, the expression of some genes studied under glucose deprivation are significantly depended on ERN1 signaling enzyme function. However, the detailed molecular mechanisms of this regulation are complex yet and warrants further study.

References

- Alimohammadi E, Bagheri SR, Salehi AS, Rizevandi P, Rezaie Z, Abdi A. Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants. *Acta Neurol Belg* 2019.
- Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. *Science* 237, 268–275, 1987.
- Auf G, Jabouille A, Guerit S, Pineau R, Delugin M, Bouchecareilh M, Favereaux A, Maitre M, Gaiser T, von Deimling A, Czabanka M, Vajkoczy P, Chevet E, Bikfalvi A, Moenner M. A shift from an angiogenic to invasive phenotype induced in malignant glioma by inhibition of the unfolded protein response sensor IRE1. *Proc Natl Acad Sci U S A* 107, 15553–15558, 2010.
- Auf G, Jabouille A, Delugin M, Guerit S, Pineau R, North S, Platonova N, Maitre M, Favereaux A, Vajkoczy P, Seno M, Bikfalvi A, Minchenko D, Minchenko O, Moenner M. High epiregulin expression in human U87 glioma cells relies on IRE1alpha and promotes autocrine growth through EGF receptor. *BMC Cancer* 13, 597, 2013.
- Awale S, Lu J, Kalauni SK, Kurashima Y, Tezuka Y, Kadota S, Esumi H. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. *Cancer Res* 66, 1751–1757, 2006a.
- Awale S, Nakashima EM, Kalauni SK, Tezuka Y, Kurashima Y, Lu J, Esumi H, Kadota S. Angelmarin, a novel anti-cancer agent able to eliminate the tolerance of cancer cells to nutrient starvation. *Bioorg Med Chem Lett* 16, 581–583, 2006b.
- Aziz MH, Chen X, Zhang Q, DeFrain C, Osland J, Luo Y, Shi X, Yuan R. Suppressing NRIP1 inhibits growth of breast cancer cells in vitro and in vivo. *Oncotarget* 6, 39714–39724, 2015.
- Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Breuss J, Minchenko OH, Mechtcheriakova D, Hohensinner P, Rychli K, Wojta J, Resink T, Binder BR, Leitinger N. Oxidized phospholipids stimulate angiogenesis via induction of VEGF, IL-8, COX-2 and ADAMTS-1 metalloprotease, implicating a novel role for lipid oxidation in progression and destabilization of atherosclerotic lesions. *Circ Res* 99, 900–908, 2006.
- Bravo R, Parra V, Gatica D, Rodriguez AE, Torrealba N, Paredes F, Wang ZV, Zorzano A, Hill JA, Jaimovich E, Quest AF, Lavandero S. Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. *Int Rev Cell Mol Biol* 301, 215–290, 2013.
- Cao H, Xu Z, Wang J, Cigliano A, Pilo MG, Ribback S, Zhang S, Qiao Y, Che L, Pascale RM, Calvisi DF, Chen X. Functional role of SGK3 in PI3K/Pten driven liver tumor development. *BMC Cancer* 19, 343, 2019.
- Chen Y, Sun Z, Qi M, Wang X, Zhang W, Chen C, Liu J, Zhao W. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway. *J Cell Mol Med* 22, 2935–2943, 2018.
- Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. *Cancer Discov* 5, 586–597, 2015.
- Choi EJ, Kim MS, Song SY, Yoo NJ, Lee SH. Low Frequent mutation of *ARHGAP35*, a candidate tumor suppressor gene, in gastric and colorectal cancers. *Pathol Oncol Res* 24, 175–176, 2018.
- Colombo SL, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I, Tudzarova S, Moncada S. Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. *Proc Natl Acad Sci USA* 108, 21069–21074, 2011.
- Dasgupta S, Putluri N, Long W, Zhang B, Wang J, Kaushik AK, Arnold JM, Bhowmik SK, Stashi E, Brennan CA, Rajapakshe K, Coarfa C, Mitsiades N, Ittmann MM, Chinnaiyan AM, Sreekumar A, O'Malley BW. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. *J Clin Invest* 125, 1174–1188, 2015.

- de Guia RM, Herzig S. How do glucocorticoids regulate lipid metabolism? *Adv Exp Med Biol* 872, 127–144, 2015.
- Dejeans N, Barroso K, Fernandez-Zapico ME, Samali A, Chevet E. Novel roles of the unfolded protein response in the control of tumor development and aggressiveness. *Semin Cancer Biol* 33, 67–73, 2015.
- Drogat B, Auguste P, Nguyen DT, Bouchecareilh M, Pineau R, Nalbantoglu J, Kaufman RJ, Chevet E, Bikfalvi A, Moenner M. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. *Cancer Res* 67, 6700–6707, 2007.
- Dvorak Z, Vrzal R, Pavek P, Ulrichova J. An evidence for regulatory cross-talk between aryl hydrocarbon receptor and glucocorticoid receptor in HepG2 cells. *Physiol Res* 57, 427–435, 2008.
- Fan XR, Zhang ZY, Wang RH, Li Y, Mao QZ. MiR-376a functions as tumor suppressor by targeting SGK3 in renal cell carcinoma. *Eur Rev Med Pharmacol Sci* 23, 3726–3732, 2019.
- Guo H, Nan Y, Zhen Y, Zhang Y, Guo L, Yu K, Huang Q, Zhong Y. miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1. *Tumour Biol* 37, 13751–13761, 2016.
- Huang Y, Zhou J, Huang Y, He J, Wang Y, Yang C, Liu D, Zhang L, He F. SARI, a novel target gene of glucocorticoid receptor, plays an important role in dexamethasone-mediated killing of B lymphoma cells. *Cancer Lett* 373, 57–66, 2016.
- Huber AL, Lebeau J, Guillaumot P, Petrilli V, Malek M, Chilloux J, Fauvet F, Payen L, Kfoury A, Renno T, Chevet E, Manie SN. p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression under low glucose. *Mol Cell* 49, 1049–1059, 2013.
- Iurlaro R, Puschel F, Leon-Annicchiarico CL, O'Connor H, Martin SJ, Palou-Gramon D, Lucendo E, Munoz-Pinedo C. Glucose deprivation induces ATF4-mediated apoptosis through TRAIL death receptors. *Mol Cell Biol* 37, e00479–e00496, 2017.
- Jalaguier S, Teyssier C, Nait Achour T, Lucas A, Bonnet S, Rodriguez C, Elarouci N, Lapierre M, Cavailles V. Complex regulation of LCoR signaling in breast cancer cells. *Oncogene* 36, 4790–4801, 2017.
- Khan SH, Ling J, Kumar R. TBP binding-induced folding of the glucocorticoid receptor AF1 domain facilitates its interaction with steroid receptor coactivator-1. *PLoS One* 6, E21939, 2011.
- Kim IK, Kim BS, Koh CH, Seok JW, Park JS, Shin KS, Bae EA, Lee GE, Jeon H, Cho J, Jung Y, Han D, Kwon BS, Lee HY, Chung Y, Kang CY. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. *Nat Med* 21, 1010–1017, 2015.
- Kubli SP, Bassi C, Roux C, Wakeham A, Gobl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, Baniasadi SP, Duncan G, Lindzen M, Yarden Y, Herranz C, Lazaro C, Chu MF, Haight J, Tinto P, Silvester J, Cescon DW, Petit A, Pettersson S, Pollard JW, Mak TW, Pujana MA, Cappello P, Gorrini C. AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. *Proc Natl Acad Sci USA* 116, 3604–3613, 2019.
- Le Billan F, Amazit L, Bleakley K, Xue QY, Pussard E, Lhadj C, Kolkhof P, Viengchareun S, Fagart J, Lombes M. Corticosteroid receptors adopt distinct cyclical transcriptional signatures. *FASEB J* 32, 5626–5639, 2018.
- Li MD, Ruan HB, Singh JP, Zhao L, Zhao T, Azarhoush S, Wu J, Evans RM, Yang X. O-GlcNAc transferase is involved in glucocorticoid receptor-mediated transrepression. *J Biol Chem* 287, 12904–12912, 2012.
- Li S, Zhuang Z, Wu T, Lin JC, Liu ZX, Zhou LF, Dai T, Lu L, Ju HQ. Nicotinamide nucleotide transhydrogenase-mediated redox homeostasis promotes tumor growth and metastasis in gastric cancer. *Redox Biol* 18, 246–255, 2018a.
- Li J, Zhou Q, Yang T, Li Y, Zhang Y, Wang J, Jiao Z. SGK1 inhibits PM2.5-induced apoptosis and oxidative stress in human lung alveolar epithelial A549 cells. *Biochem Biophys Res Commun* 496, 1291–1295, 2018b.
- Liang YN, Tang YL, Ke ZY, Chen YQ, Luo XQ, Zhang H, Huang LB. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. *J Steroid Biochem Mol Biol* 172, 62–68, 2017.
- Liu H, Li C, Shen C, Yin F, Wang K, Liu Y, Zheng B, Zhang W, Hou X, Chen X, Wu J, Wang X, Zhong C, Zhang J, Shi H, Ai J, Zhao S. MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3. *J Neurooncol* 122, 431–439, 2015.
- Ma X, Zhang L, Song J, Nguyen E, Lee RS, Rodgers SJ, Li F, Huang C, Schittenhelm RB, Chan H, Chheang C, Wu J, Brown KK, Mitchell CA, Simpson KJ, Daly RJ. Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation. *Nat Commun* 10, 296, 2019.
- Manie SN, Lebeau J, Chevet E. Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 3. Orchestrating the unfolded protein response in oncogenesis: an update. *Am J Physiol Cell Physiol* 307, C901–C907, 2014.

- Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, Nurnberg P, Mann NP, Banerjee R, Saka HN, Chapple JP, King PJ, Clark AJ, Metherell LA. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. *Nat Genet* 44, 740–742, 2012.
- Meimaridou E, Goldsworthy M, Chortis V, Fragouli E, Foster PA, Arlt W, Cox R, Metherell LA. NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice. *J Endocrinol* 236, 13–28, 2018.
- Minchenko AG, Germanyuk YL. Effect of hydrocortisone on the expression of mitochondrial genes in the liver of normal and alloxan diabetic rats. *Endocrinol Exper* 18, 3–18, 1984.
- Minchenko AG. Effect of hydrocortisone on biosynthesis of mitochondrial and cytoplasmic RNA in liver of adrenalectomized rats. *Endocrinol Exper* 22, 75–86, 1988.
- Minchenko AG, Tronjko ND. Subcellular distribution of ³H-hydrocortisone and its metabolites in the liver and kidneys of normal and alloxan diabetic rats. *Endocrinol Exper* 22, 19–28, 1988.
- Minchenko OH, Kharkova AP, Bakalets TV, Kryvdiuk IV. Endoplasmic reticulum stress, its sensor and signaling systems and the role in regulation of gene expressions at malignant tumor growth and hypoxia. *Ukr Biokhim Zh* 85, 5–16, 2013.
- Minchenko DO, Danilovskyi SV, Kryvdiuk IV, Bakalets TV, Lypova NM, Karbovskyi LL, Minchenko OH. Inhibition of ERN1 modifies the hypoxic regulation of the expression of TP53-related genes in U87 glioma cells. *Endoplasm Reticul Stress Dis* 1, 18–26, 2014.
- Minchenko DO, Kharkova AP, Tsymbal DO, Karbovskyi LL, Minchenko OH. Expression of insulin-like growth factor binding protein genes and its hypoxic regulation in U87 glioma cells depends on ERN1 mediated signaling pathway of endoplasmic reticulum stress. *Endocr Regul* 49, 73–83, 2015a.
- Minchenko DO, Kharkova AP, Tsymbal DO, Karbovskyi LL, Minchenko OH. IRE1 inhibition affects the expression of insulin-like growth factor binding protein genes and modifies its sensitivity to glucose deprivation in U87 glioma cells. *Endocr Regul* 49, 185–197, 2015b.
- Minchenko OH, Tsymbal DO, Moenner M, Minchenko DO, Kovalevska OV, Lypova NM. Inhibition of the endonuclease of ERN1 signaling enzyme affects the expression of proliferation-related genes in U87 glioma cells. *Endoplasm Reticul Stress Dis* 2, 18–29, 2015c.
- Minchenko DO, Tsymbal DO, Davydov VV, Minchenko OH. Expression of genes encoding IGF1, IGF2, and IGF1Rs in blood of obese adolescents with insulin resistance. *Endocr Reg* 53, 34–45, 2019.
- Mitsuishi Y, Shibata H, Kurihara I, Kobayashi S, Yokota K, Murai-Takeda A, Hayashi T, Jo R, Nakamura T, Morisaki M, Itoh H. Epidermal growth factor receptor/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization. *Mol Cell Endocrinol* 473, 89–99, 2018.
- Moenner M, Pluquet O, Bouchecareilh M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. *Cancer Res* 67, 10631–10634, 2007.
- Muller K, Sixou S, Kuhn C, Jalaguier S, Mayr D, Ditsch N, Weissenbacher T, Harbeck N, Mahner S, Cavaillès V, Jeschke U. Prognostic relevance of RIP140 and ERbeta expression in unifocal versus multifocal breast cancers: a preliminary report. *Int J Mol Sci* 20, E418, 2019.
- Nayak L, Reardon DA. High-grade gliomas. *Continuum (Minneapolis)* 23, 1548–1563, 2017.
- Onodera K, Sakurada A, Notsuda H, Watanabe T, Matsuda Y, Noda M, Endo C, Okada Y. Growth inhibition of KRAS and EGFR mutant lung adenocarcinoma by cosuppression of STAT3 and the SRC/ARHGAP35 axis. *Oncol Rep* 40, 1761–1768, 2018.
- Organ SL, Hai J, Radulovich N, Marshall CB, Leung L, Sasazuki T, Shirasawa S, Zhu CQ, Navab R, Ikura M, Tsao MS. p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line. *PLoS One* 9, e86103, 2014.
- Psarra AM, Sekeris CE. Glucocorticoids induce mitochondrial gene transcription in HepG2 cells: role of the mitochondrial glucocorticoid receptor. *Biochim Biophys Acta* 1813, 1814–1821, 2011.
- Pufall MA. Glucocorticoids and cancer. *Adv Exp Med Biol* 872, 315–333, 2015.
- Qi L, Ding Y. Construction of key signal regulatory network in metastatic colorectal cancer. *Oncotarget* 9, 6086–6094, 2017.
- Teramoto K, Katoh H. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucose-limited conditions. *Cell Signal* 62, 109329, 2019.
- Thomas AL, Coarfa C, Qian J, Wilkerson JJ, Rajapakse K, Krett NL, Gunaratne PH, Rosen ST. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma. *Nucl Recept Signal* 13, e006, 2015.
- Tsymbal DO, Minchenko DO, Riabovol OO, Ratushna OO, Minchenko OH. IRE1 knockdown modifies glucose and glutamine deprivation effects on the expression of proliferation related genes in U87 glioma cells. *Biotechnologia Acta* 9, 26–37, 2016.

- Vonlanthen J, Okoniewski MJ, Menigatti M, Cattaneo E, Pellegrini-Ochsner D, Haider R, Jiricny J, Staiano T, Buffoli F, Marra G. A comprehensive look at transcription factor gene expression changes in colorectal adenomas. *BMC Cancer* 14, 46, 2014.
- Weinberg-Shukron A, Abu-Libdeh A, Zhadeh F, Carmel L, Kogot-Levin A, Kamal L, Kanaan M, Zeligson S, Renbaum P, Levy-Lahad E, Zangen D. Combined mineralocorticoid and glucocorticoid deficiency is caused by a novel founder nicotinamide nucleotide transhydrogenase mutation that alters mitochondrial morphology and increases oxidative stress. *J Med Genet* 52, 636–641, 2015.
- Xiaobo Y, Qiang L, Xiong Q, Zheng R, Jianhua Z, Zhifeng L, Yijiang S, Zheng J. Serum and glucocorticoid kinase 1 promoted the growth and migration of non-small cell lung cancer cells. *Gene* 576, 339–346, 2016.
- Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O’Neal J, Klarer AC, Clem AL, Telang S, Chesney J. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. *Cell Death Dis* 5, e1337, 2014. Yang C, Ma X, Guan G, Liu H, Yang Y, Niu Q, Wu Z, Jiang Y, Bian C, Zang Y, Zhuang L. MicroRNA-766 promotes cancer progression by targeting NR3C2 in hepatocellular carcinoma. *FASEB J* 33, 1456–1467, 2019.
- Zhao J, Xu H, He M, Wu Y. Glucocorticoid receptor DNA binding factor 1 expression and osteosarcoma prognosis. *Tumour Biol* 35, 12449–12458, 2014.
- Zhao S, Cai J, Li J, Bao G, Li D, Li Y, Zhai X, Jiang C, Fan L. Bioinformatic profiling identifies a glucose-related risk signature for the malignancy of glioma and the survival of patients. *Mol Neurobiol* 54, 8203–8210, 2017.